Equillium, Inc.
Clinical-stage biotech developing therapies for autoimmune & inflammatory disorders.
EQ | US
Overview
Corporate Details
- ISIN(s):
- US29446K1060
- LEI:
- Country:
- United States of America
- Address:
- 2223 AVENIDA DE LA PLAYA, 92037 LA JOLLA
Description
Equillium is a clinical-stage biotechnology company that develops novel therapeutics for severe autoimmune and inflammatory disorders with high unmet medical need. The company leverages a deep understanding of immunobiology to create treatments designed to restore balance to the immune system. Its pipeline includes EQ504, a potent and selective Aryl Hydrocarbon Receptor (AhR) modulator with a non-immunosuppressive mechanism of action. Equillium also develops a multi-cytokine inhibitor platform that utilizes first-in-class structured-domain peptides to selectively inhibit multiple disease-driving cytokines while preserving other immune regulatory pathways.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Equillium, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Equillium, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Equillium, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
